Company Snapshot
Ollin Biosciences is a Biotech company, based in Chicago, Illinois, USA, founded 2023.
Recent changes
- Jun 26, 2026Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline Pulse story
- Jun 25, 2026Jun 25, 2026Raised $330M Series B Crunchbase News
- Jun 25, 2026Jun 25, 2026New investor: TCG Crossover Crunchbase News
- Jun 25, 2026Jun 25, 2026Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies Pulse story
- May 14, 2026May 14, 2026Raised $156.2M SEC EDGAR Form D
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 25, 2026 | Series B | $330M | — | TCG CrossoverLead | Pulse story |
| May 14, 2026 | funding round | $156.2M | — | SEC EDGAR Form D |
Investors
Latest Pulse
- Jun 26, 2026Jupiter Neurosciences Files S-1 to Fund Its Neuroinflammation and Longevity PipelineClinical-stage biotech Jupiter Neurosciences (Nasdaq: JUNS) filed a Form S-1 with the SEC to register fresh capital as it advances its lead candidate JOTROL, a proprietary resveratrol platform targeting rare and neuroinflammatory CNS disorders and, increasingly, longevity. The filing adds another central-nervous-system name to a 2026 biotech pipeline that keeps widening alongside AI and chips.→
- Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.→
- Jun 25, 2026Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease TherapiesOllin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.→
Coverage Timeline
newest firstAll Coverage
FUNDING$330M
Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline
Ollin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
FUNDING$330M
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
Ollin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.
Related Companies
Ollin Biosciences FAQ
Who are Ollin Biosciences's investors?
Ollin Biosciences's investors include TCG Crossover, Andreessen Horowitz, ARCH Venture Partners, Blackstone Multi-Asset Investing, Commodore Capital, and 4 more (As of 2026-07-30T20:03:01Z).
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
- Crunchbase Newsresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.